摘要
脂蛋白a被认为是心血管疾病的独立危险因素,目前临床上常用他汀类药物来控制脂蛋白a的水平,但结果并不理想。前蛋白转化酶枯草溶菌素9(PCSK9)是一种肝源性分泌蛋白并与脂蛋白a的水平呈正相关,新近完成的临床试验也显示PCSK9的抑制剂能有效降低脂蛋白a的水平。现探究在心血管疾病中PCSK9抑制剂对脂蛋白a的作用及机制,以进一步指导临床治疗。
Lipoprotein (a) is considered to be an independent risk factor for cardiovascular disease. Currently, statins are commonly used in clinical practice to control the level of lipoprotein (a), but the result is not ideal.Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a liver-derived secreted protein, and PCSK9 is positively correlated with the level of lipoprotein (a). Recent clinical trials have also shown that PCSK9 inhibitors can effectively reduce the level of lipoprotein (a). This article explores the role and mechanism of PCSK9 inhibitors on lipoprotein (a) in cardiovascular disease to further guide clinical treatment.
作者
凌浩
侯秀伟
廉瑞
赵洋
宋春莉
吴莉侠
LING Hao;HOU Xiuwei;LIAN Rui;ZHAO Yang;SONG Chunli;WU Lixia(Department of Cardiology,The Second Hospital of Jilin University,Changchun 130012,Jilin,China)
出处
《心血管病学进展》
CAS
2019年第4期633-637,共5页
Advances in Cardiovascular Diseases
基金
吉林省教育厅十三五科学技术研究项目资助项目(JJKH20180104KJ)
2018年度吉林省财政厅卫生专项项目
吉林省新型冠状动脉支架科技创新中心资助项目(JKFC2017250)